

# Ie-Ming Shih

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/2914247/ie-ming-shih-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

274  
papers

27,330  
citations

87  
h-index

160  
g-index

284  
ext. papers

31,323  
ext. citations

8.1  
avg, IF

7.23  
L-index

#	Paper	IF	Citations
274	The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. <i>American Journal of Surgical Pathology</i> , <b>2010</b> , 34, 433-43	6.7	1235
273	ARID1A mutations in endometriosis-associated ovarian carcinomas. <i>New England Journal of Medicine</i> , <b>2010</b> , 363, 1532-43	59.2	1208
272	TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2013</b> , 110, 6021-6	11.5	968
271	Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. <i>American Journal of Pathology</i> , <b>2004</b> , 164, 1511-8	5.8	951
270	Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. <i>Science</i> , <b>2010</b> , 330, 228-31	33.3	915
269	Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. <i>Human Pathology</i> , <b>2011</b> , 42, 918-31	3.7	767
268	Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. <i>Journal of the National Cancer Institute</i> , <b>2003</b> , 95, 484-6	9.7	668
267	Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer. <i>Cell</i> , <b>2016</b> , 166, 755-765	56.2	544
266	The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded. <i>American Journal of Pathology</i> , <b>2016</b> , 186, 733-47	5.8	506
265	Ovarian cancer. <i>Annual Review of Pathology: Mechanisms of Disease</i> , <b>2009</b> , 4, 287-313	34	505
264	National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. <i>Clinical Chemistry</i> , <b>2008</b> , 54, e11-79	5.5	451
263	Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. <i>Advances in Anatomic Pathology</i> , <b>2009</b> , 16, 267-82	5.1	403
262	The role of chromosomal instability in tumor initiation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2002</b> , 99, 16226-31	11.5	399
261	Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. <i>Nature Medicine</i> , <b>2015</b> , 21, 231-8	50.5	397
260	Notch signaling, gamma-secretase inhibitors, and cancer therapy. <i>Cancer Research</i> , <b>2007</b> , 67, 1879-82	10.1	354
259	Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. <i>American Journal of Pathology</i> , <b>2009</b> , 174, 1597-601	5.8	339
258	Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. <i>American Journal of Surgical Pathology</i> , <b>2005</b> , 29, 218-24	6.7	336

257	Are all pelvic (nonuterine) serous carcinomas of tubal origin?. <i>American Journal of Surgical Pathology</i> , <b>2010</b> , 34, 1407-16	6.7	333
256	Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. <i>International Journal of Gynecological Pathology</i> , <b>2008</b> , 27, 151-60	3.2	329
255	Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. <i>American Journal of Pathology</i> , <b>2011</b> , 179, 1608-15	5.8	328
254	High grade serous ovarian carcinomas originate in the fallopian tube. <i>Nature Communications</i> , <b>2017</b> , 8, 1093	17.4	325
253	Cancer-Associated Mutations in Endometriosis without Cancer. <i>New England Journal of Medicine</i> , <b>2017</b> , 376, 1835-1848	59.2	310
252	ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. <i>Cancer Research</i> , <b>2011</b> , 71, 6718-27	10.1	306
251	Diverse tumorigenic pathways in ovarian serous carcinoma. <i>American Journal of Pathology</i> , <b>2002</b> , 160, 1223-8	5.8	280
250	MicroRNA expression and identification of putative miRNA targets in ovarian cancer. <i>PLoS ONE</i> , <b>2008</b> , 3, e2436	3.7	273
249	Epithelioid trophoblastic tumor: a neoplasm distinct from choriocarcinoma and placental site trophoblastic tumor simulating carcinoma. <i>American Journal of Surgical Pathology</i> , <b>1998</b> , 22, 1393-403	6.7	268
248	ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors. <i>Cancer Discovery</i> , <b>2015</b> , 5, 752-67	24.4	260
247	TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma--evidence supporting the clonal relationship of the two lesions. <i>Journal of Pathology</i> , <b>2012</b> , 226, 421-6	9.4	252
246	Notch3 gene amplification in ovarian cancer. <i>Cancer Research</i> , <b>2006</b> , 66, 6312-8	10.1	236
245	The pathology of intermediate trophoblastic tumors and tumor-like lesions. <i>International Journal of Gynecological Pathology</i> , <b>2001</b> , 20, 31-47	3.2	224
244	Increased plasma DNA integrity in cancer patients. <i>Cancer Research</i> , <b>2003</b> , 63, 3966-8	10.1	216
243	A fluorescence light-up Ag nanocluster probe that discriminates single-nucleotide variants by emission color. <i>Journal of the American Chemical Society</i> , <b>2012</b> , 134, 11550-8	16.4	213
242	Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. <i>Science Translational Medicine</i> , <b>2013</b> , 5, 167ra4	17.5	208
241	Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma. <i>American Journal of Surgical Pathology</i> , <b>2011</b> , 35, 625-32	6.7	206
240	Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses. <i>Journal of the National Cancer Institute</i> , <b>2012</b> , 104, 1503-13	9.7	191

239	Fallopian tube precursors of ovarian low- and high-grade serous neoplasms. <i>Histopathology</i> , <b>2013</b> , 62, 44-58	7.3	190
238	Proteomic approaches to tumor marker discovery. <i>Archives of Pathology and Laboratory Medicine</i> , <b>2002</b> , 126, 1518-26	5	181
237	Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2004</b> , 101, 3089-94	11.5	163
236	Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. <i>Cancer Research</i> , <b>2004</b> , 64, 6915-8	10.1	160
235	Long interspersed element-1 protein expression is a hallmark of many human cancers. <i>American Journal of Pathology</i> , <b>2014</b> , 184, 1280-6	5.8	158
234	Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. <i>American Journal of Obstetrics and Gynecology</i> , <b>2008</b> , 198, 351-6	6.4	157
233	Low-grade serous carcinomas of the ovary contain very few point mutations. <i>Journal of Pathology</i> , <b>2012</b> , 226, 413-20	9.4	154
232	Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms. <i>Cancer Biology and Therapy</i> , <b>2006</b> , 5, 779-85	4.6	149
231	Principle and applications of digital PCR. <i>Expert Review of Molecular Diagnostics</i> , <b>2004</b> , 4, 41-7	3.8	149
230	The emerging roles of ARID1A in tumor suppression. <i>Cancer Biology and Therapy</i> , <b>2014</b> , 15, 655-64	4.6	148
229	Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas. <i>Cancer Research</i> , <b>2009</b> , 69, 4036-42	10.1	143
228	Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases. <i>American Journal of Surgical Pathology</i> , <b>2009</b> , 33, 1504-14	6.7	142
227	Gestational trophoblastic neoplasia--pathogenesis and potential therapeutic targets. <i>Lancet Oncology</i> , <b>2007</b> , 8, 642-50	21.7	142
226	Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin. <i>American Journal of Pathology</i> , <b>2010</b> , 177, 1087-94	5.8	137
225	APC/CTNNB1 (beta-catenin) pathway alterations in human prostate cancers. <i>Genes Chromosomes and Cancer</i> , <b>2002</b> , 34, 9-16	5	133
224	Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2017</b> , 114, E10981-E10990	11.5	132
223	Functional genomic analysis identified epidermal growth factor receptor activation as the most common genetic event in oral squamous cell carcinoma. <i>Cancer Research</i> , <b>2009</b> , 69, 2568-76	10.1	132
222	HLA-G is a potential tumor marker in malignant ascites. <i>Clinical Cancer Research</i> , <b>2003</b> , 9, 4460-4	12.9	130

221	p63 expression is useful in the distinction of epithelioid trophoblastic and placental site trophoblastic tumors by profiling trophoblastic subpopulations. <i>American Journal of Surgical Pathology</i> , <b>2004</b> , 28, 1177-83	6.7	128
220	The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis. <i>American Journal of Surgical Pathology</i> , <b>2007</b> , 31, 1007-12	6.7	126
219	Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2005</b> , 102, 14004-9	11.5	119
218	Papillary tubal hyperplasia: the putative precursor of ovarian atypical proliferative (borderline) serous tumors, noninvasive implants, and endosalpingiosis. <i>American Journal of Surgical Pathology</i> , <b>2011</b> , 35, 1605-14	6.7	116
217	Diagnosis of serous tubal intraepithelial carcinoma based on morphologic and immunohistochemical features: a reproducibility study. <i>American Journal of Surgical Pathology</i> , <b>2011</b> , 35, 1766-75	6.7	116
216	Origin and pathogenesis of pelvic (ovarian, tubal, and primary peritoneal) serous carcinoma. <i>Annual Review of Pathology: Mechanisms of Disease</i> , <b>2014</b> , 9, 27-45	34	113
215	Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma. <i>International Journal of Gynecological Cancer</i> , <b>2012</b> , 22, 1310-5	3.5	113
214	Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges. <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 7273-9	12.9	113
213	Ki-67 labeling index in the differential diagnosis of exaggerated placental site, placental site trophoblastic tumor, and choriocarcinoma: a double immunohistochemical staining technique using Ki-67 and Mel-CAM antibodies. <i>Human Pathology</i> , <b>1998</b> , 29, 27-33	3.7	112
212	Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers. <i>Science Translational Medicine</i> , <b>2018</b> , 10,	17.5	110
211	Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study. <i>International Journal of Gynecological Pathology</i> , <b>2016</b> , 35, 48-55	3.2	110
210	Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma. <i>Nature Communications</i> , <b>2017</b> , 8, 990	17.4	109
209	HLA-G immunoreactivity is specific for intermediate trophoblast in gestational trophoblastic disease and can serve as a useful marker in differential diagnosis. <i>American Journal of Surgical Pathology</i> , <b>2002</b> , 26, 914-20	6.7	109
208	Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations. <i>Cancer Research</i> , <b>2005</b> , 65, 1994-2000	10.1	108
207	Cystic and adenofibromatous clear cell carcinomas of the ovary: distinctive tumors that differ in their pathogenesis and behavior: a clinicopathologic analysis of 122 cases. <i>American Journal of Surgical Pathology</i> , <b>2009</b> , 33, 844-53	6.7	106
206	Amplicon profiles in ovarian serous carcinomas. <i>International Journal of Cancer</i> , <b>2007</b> , 120, 2613-7	7.5	104
205	Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis. <i>Cancer Research</i> , <b>2006</b> , 66, 3754-63	10.1	104
204	A BTB/POZ protein, NAC-1, is related to tumor recurrence and is essential for tumor growth and survival. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2006</b> , 103, 18739-44	11.5	104

203	Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas. <i>Clinical Cancer Research</i> , <b>2004</b> , 10, 6432-6	12.9	103
202	IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype. <i>Modern Pathology</i> , <b>2009</b> , 22, 469-75	9.8	102
201	Shortened telomeres in serous tubal intraepithelial carcinoma: an early event in ovarian high-grade serous carcinogenesis. <i>American Journal of Surgical Pathology</i> , <b>2010</b> , 34, 829-36	6.7	102
200	Assessment of plasma DNA levels, allelic imbalance, and CA 125 as diagnostic tests for cancer. <i>Journal of the National Cancer Institute</i> , <b>2002</b> , 94, 1697-703	9.7	102
199	Jagged-1 and Notch3 juxtacrine loop regulates ovarian tumor growth and adhesion. <i>Cancer Research</i> , <b>2008</b> , 68, 5716-23	10.1	101
198	Amplification of 11q13 in ovarian carcinoma. <i>Genes Chromosomes and Cancer</i> , <b>2008</b> , 47, 481-9	5	101
197	Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma (high-grade tumor). <i>International Journal of Gynecological Pathology</i> , <b>2003</b> , 22, 37-41	3.2	101
196	Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules. <i>Cancer Cell</i> , <b>2015</b> , 28, 82-96	24.3	96
195	Validation of an algorithm for the diagnosis of serous tubal intraepithelial carcinoma. <i>International Journal of Gynecological Pathology</i> , <b>2012</b> , 31, 243-53	3.2	95
194	Apolipoprotein E is required for cell proliferation and survival in ovarian cancer. <i>Cancer Research</i> , <b>2005</b> , 65, 331-7	10.1	94
193	A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development. <i>Journal of Pathology</i> , <b>2014</b> , 233, 228-37	9.4	93
192	Placental site nodule and characterization of distinctive types of intermediate trophoblast. <i>Human Pathology</i> , <b>1999</b> , 30, 687-94	3.7	93
191	PD-L1 Expression in Human Placentas and Gestational Trophoblastic Diseases. <i>International Journal of Gynecological Pathology</i> , <b>2017</b> , 36, 146-153	3.2	92
190	Ovarian Cancer Is an Imported Disease: Fact or Fiction?. <i>Current Obstetrics and Gynecology Reports</i> , <b>2012</b> , 1, 1-9	0.6	91
189	Clinicopathological significance of loss of ARID1A immunoreactivity in ovarian clear cell carcinoma. <i>International Journal of Molecular Sciences</i> , <b>2010</b> , 11, 5120-8	6.3	89
188	Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from diffuse malignant peritoneal mesothelioma. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 5944-50	12.9	89
187	ARID1A loss correlates with mismatch repair deficiency and intact p53 expression in high-grade endometrial carcinomas. <i>Modern Pathology</i> , <b>2014</b> , 27, 255-61	9.8	86
186	Roles of deletion of Arid1a, a tumor suppressor, in mouse ovarian tumorigenesis. <i>Journal of the National Cancer Institute</i> , <b>2014</b> , 106,	9.7	83



185	HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma. <i>Gynecologic Oncology</i> , <b>2005</b> , 96, 42-7	4.9	83
184	Pathogenesis and the role of ARID1A mutation in endometriosis-related ovarian neoplasms. <i>Advances in Anatomic Pathology</i> , <b>2013</b> , 20, 45-52	5.1	82
183	The Origin and Pathogenesis of Endometriosis. <i>Annual Review of Pathology: Mechanisms of Disease</i> , <b>2020</b> , 15, 71-95	34	78
182	Jagged1 expression regulated by Notch3 and Wnt/βcatenin signaling pathways in ovarian cancer. <i>Oncotarget</i> , <b>2010</b> , 1, 210-8	3.3	77
181	DNA copy numbers profiles in affinity-purified ovarian clear cell carcinoma. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 1997-2008	12.9	76
180	Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2006</b> , 449, 31-9	5.1	73
179	Somatic mutations of PPP2R1A in ovarian and uterine carcinomas. <i>American Journal of Pathology</i> , <b>2011</b> , 178, 1442-7	5.8	72
178	Serous tubal intraepithelial carcinoma upregulates markers associated with high-grade serous carcinomas including Rsf-1 (HBXAP), cyclin E and fatty acid synthase. <i>Modern Pathology</i> , <b>2010</b> , 23, 844-55 <sup>9.8</sup>	9.8	72
177	Identifying tumor origin using a gene expression-based classification map. <i>Cancer Research</i> , <b>2003</b> , 63, 4144-9	10.1	72
176	Functional analysis of in-frame indel ARID1A mutations reveals new regulatory mechanisms of its tumor suppressor functions. <i>Neoplasia</i> , <b>2012</b> , 14, 986-93	6.4	71
175	Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 827-31	12.9	71
174	Immunohistochemistry of choriocarcinoma: an aid in differential diagnosis and in elucidating pathogenesis. <i>American Journal of Surgical Pathology</i> , <b>2007</b> , 31, 1726-32	6.7	71
173	Cyclin E and p16 immunoreactivity in epithelioid trophoblastic tumor--an aid in differential diagnosis. <i>American Journal of Surgical Pathology</i> , <b>2006</b> , 30, 1105-10	6.7	69
172	Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy. <i>Journal of Pathology</i> , <b>2014</b> , 232, 473-81	9.4	68
171	Defining the cut point between low-grade and high-grade ovarian serous carcinomas: a clinicopathologic and molecular genetic analysis. <i>American Journal of Surgical Pathology</i> , <b>2009</b> , 33, 1220-4 <sup>6.7</sup>	6.7	68
170	Trophogram, an immunohistochemistry-based algorithmic approach, in the differential diagnosis of trophoblastic tumors and tumorlike lesions. <i>Annals of Diagnostic Pathology</i> , <b>2007</b> , 11, 228-34	2.2	68
169	Functional analysis of 11q13.5 amplicon identifies Rsf-1 (HBXAP) as a gene involved in paclitaxel resistance in ovarian cancer. <i>Cancer Research</i> , <b>2009</b> , 69, 1407-15	10.1	64
168	Loss of ARID1A expression correlates with stages of tumor progression in uterine endometrioid carcinoma. <i>American Journal of Surgical Pathology</i> , <b>2013</b> , 37, 1342-8	6.7	62

167	Oncoproteomic analysis reveals co-upregulation of RELA and STAT5 in carboplatin resistant ovarian carcinoma. <i>PLoS ONE</i> , <b>2010</b> , 5, e11198	3.7	62
166	Molecular basis of gestational trophoblastic diseases. <i>Current Molecular Medicine</i> , <b>2002</b> , 2, 1-12	2.5	61
165	Endocervical-type mucinous borderline tumors are related to endometrioid tumors based on mutation and loss of expression of ARID1A. <i>International Journal of Gynecological Pathology</i> , <b>2012</b> , 31, 297-303	3.2	60
164	Expression of the folate receptor genes FOLR1 and FOLR3 differentiates ovarian carcinoma from breast carcinoma and malignant mesothelioma in serous effusions. <i>Human Pathology</i> , <b>2009</b> , 40, 1453-60	3.7	59
163	Human transposon insertion profiling: Analysis, visualization and identification of somatic LINE-1 insertions in ovarian cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2017</b> , 114, E733-E740	11.5	57
162	GATA-3 expression in trophoblastic tissues: an immunohistochemical study of 445 cases, including diagnostic utility. <i>American Journal of Surgical Pathology</i> , <b>2015</b> , 39, 101-8	6.7	56
161	Gene expression signatures of primary and metastatic uterine leiomyosarcoma. <i>Human Pathology</i> , <b>2014</b> , 45, 691-700	3.7	55
160	CCNE1 amplification and centrosome number abnormality in serous tubal intraepithelial carcinoma: further evidence supporting its role as a precursor of ovarian high-grade serous carcinoma. <i>Modern Pathology</i> , <b>2016</b> , 29, 1254-61	9.8	54
159	Precursor lesions of high-grade serous ovarian carcinoma: morphological and molecular characteristics. <i>Journal of Oncology</i> , <b>2010</b> , 2010, 126295	4.5	54
158	Identification of Pbx1, a potential oncogene, as a Notch3 target gene in ovarian cancer. <i>Cancer Research</i> , <b>2008</b> , 68, 8852-60	10.1	53
157	NAC-1 controls cell growth and survival by repressing transcription of Gadd45GIP1, a candidate tumor suppressor. <i>Cancer Research</i> , <b>2007</b> , 67, 8058-64	10.1	53
156	Molecular genetic analysis of placental site trophoblastic tumors and epithelioid trophoblastic tumors confirms their trophoblastic origin. <i>American Journal of Pathology</i> , <b>2002</b> , 161, 1033-7	5.8	53
155	Ovarian Brenner tumour: a morphologic and immunohistochemical analysis suggesting an origin from fallopian tube epithelium. <i>European Journal of Cancer</i> , <b>2013</b> , 49, 3839-49	7.5	52
154	Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma. <i>Human Pathology</i> , <b>2012</b> , 43, 2197-206	3.7	52
153	PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8 T-cell Function. <i>Cancer Immunology Research</i> , <b>2019</b> , 7, 257-268	12.5	51
152	Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer. <i>Cell Reports</i> , <b>2018</b> , 22, 3393-3400	10.6	50
151	HLA-G and immune evasion in cancer cells. <i>Journal of the Formosan Medical Association</i> , <b>2010</b> , 109, 248-53	3.2	50
150	Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival?. <i>Gynecologic Oncology</i> , <b>2017</b> , 147, 85-91	4.9	49



149	Defining NOTCH3 target genes in ovarian cancer. <i>Cancer Research</i> , <b>2012</b> , 72, 2294-303	10.1	49
148	Rsf-1, a chromatin remodeling protein, induces DNA damage and promotes genomic instability. <i>Journal of Biological Chemistry</i> , <b>2010</b> , 285, 38260-9	5.4	47
147	The roles of human sucrose nonfermenting protein 2 homologue in the tumor-promoting functions of Rsf-1. <i>Cancer Research</i> , <b>2008</b> , 68, 4050-7	10.1	47
146	Frequent CCNE1 amplification in endometrial intraepithelial carcinoma and uterine serous carcinoma. <i>Modern Pathology</i> , <b>2014</b> , 27, 1014-9	9.8	46
145	Notch3 interactome analysis identified WWP2 as a negative regulator of Notch3 signaling in ovarian cancer. <i>PLoS Genetics</i> , <b>2014</b> , 10, e1004751	6	46
144	The roles of ARID1A in gynecologic cancer. <i>Journal of Gynecologic Oncology</i> , <b>2013</b> , 24, 376-81	4	46
143	Cancer Implications for Patients with Endometriosis. <i>Seminars in Reproductive Medicine</i> , <b>2017</b> , 35, 110-116	4	45
142	Pathogenesis of ovarian cancer: clues from selected overexpressed genes. <i>Future Oncology</i> , <b>2009</b> , 5, 1641-57	3.6	45
141	HSD3B1 as a novel trophoblast-associated marker that assists in the differential diagnosis of trophoblastic tumors and tumorlike lesions. <i>American Journal of Surgical Pathology</i> , <b>2008</b> , 32, 236-42	6.7	45
140	Ovarian Cancer Chemoresistance Relies on the Stem Cell Reprogramming Factor PBX1. <i>Cancer Research</i> , <b>2016</b> , 76, 6351-6361	10.1	45
139	Loss of ARID1A in Tumor Cells Renders Selective Vulnerability to Combined Ionizing Radiation and PARP Inhibitor Therapy. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 5584-5594	12.9	44
138	Expression of Fatty Acid Synthase Depends on NAC1 and Is Associated with Recurrent Ovarian Serous Carcinomas. <i>Journal of Oncology</i> , <b>2010</b> , 2010, 285191	4.5	44
137	Amplification of the ch19p13.2 NACC1 locus in ovarian high-grade serous carcinoma. <i>Modern Pathology</i> , <b>2011</b> , 24, 638-45	9.8	44
136	Genomic landscape and evolutionary trajectories of ovarian cancer precursor lesions. <i>Journal of Pathology</i> , <b>2019</b> , 248, 41-50	9.4	44
135	Homozygous deletion of MKK4 in ovarian serous carcinoma. <i>Cancer Biology and Therapy</i> , <b>2006</b> , 5, 630-4	4.6	43
134	UNDO: a Bioconductor R package for unsupervised deconvolution of mixed gene expressions in tumor samples. <i>Bioinformatics</i> , <b>2015</b> , 31, 137-9	7.2	42
133	Mutational analysis of BRAF and KRAS in ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implants. <i>Journal of Pathology</i> , <b>2014</b> , 232, 16-22	9.4	42
132	BRAF mutation is associated with a specific cell type with features suggestive of senescence in ovarian serous borderline (atypical proliferative) tumors. <i>American Journal of Surgical Pathology</i> , <b>2014</b> , 38, 1603-11	6.7	42

131	Molecular genetic analysis of ovarian serous cystadenomas. <i>Laboratory Investigation</i> , <b>2004</b> , 84, 778-84	5.9	40
130	HLA-G upregulation in pre-malignant and malignant lesions of the gastrointestinal tract. <i>International Journal of Gastrointestinal Cancer</i> , <b>2005</b> , 35, 15-23		40
129	Prognostic and therapeutic impact of the chromosome 20q13.2 ZNF217 locus amplification in ovarian clear cell carcinoma. <i>Cancer</i> , <b>2012</b> , 118, 2846-57	6.4	39
128	Overexpression of a chromatin remodeling factor, RSF-1/HBXAP, correlates with aggressive oral squamous cell carcinoma. <i>American Journal of Pathology</i> , <b>2011</b> , 178, 2407-15	5.8	39
127	The diagnostic and biological implications of laminin expression in serous tubal intraepithelial carcinoma. <i>American Journal of Surgical Pathology</i> , <b>2012</b> , 36, 1826-34	6.7	39
126	Ovarian cancer specific kallikrein profile in effusions. <i>Gynecologic Oncology</i> , <b>2007</b> , 105, 501-7	4.9	39
125	MUC4 is upregulated in ovarian carcinoma effusions and differentiates carcinoma cells from mesothelial cells. <i>Diagnostic Cytopathology</i> , <b>2007</b> , 35, 756-60	1.4	39
124	CCNE1 copy-number gain and overexpression identify ovarian clear cell carcinoma with a poor prognosis. <i>Modern Pathology</i> , <b>2017</b> , 30, 297-303	9.8	38
123	Ki-67 labeling index as an adjunct in the diagnosis of serous tubal intraepithelial carcinoma. <i>International Journal of Gynecological Pathology</i> , <b>2012</b> , 31, 416-22	3.2	38
122	Clinical and biological significance of HLA-G expression in ovarian cancer. <i>Seminars in Cancer Biology</i> , <b>2007</b> , 17, 436-43	12.7	38
121	Mevalonate Pathway Antagonist Suppresses Formation of Serous Tubal Intraepithelial Carcinoma and Ovarian Carcinoma in Mouse Models. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 4652-62	12.9	37
120	Distinct DNA methylation profiles in ovarian serous neoplasms and their implications in ovarian carcinogenesis. <i>American Journal of Obstetrics and Gynecology</i> , <b>2010</b> , 203, 584.e1-22	6.4	37
119	Clonality analysis of combined Brenner and mucinous tumours of the ovary reveals their monoclonal origin. <i>Journal of Pathology</i> , <b>2015</b> , 237, 146-51	9.4	36
118	Expression of Rsf-1, a chromatin-remodeling gene, in ovarian and breast carcinoma. <i>Human Pathology</i> , <b>2006</b> , 37, 1169-75	3.7	35
117	Independent development of endometrial epithelium and stroma within the same endometriosis. <i>Journal of Pathology</i> , <b>2018</b> , 245, 265-269	9.4	34
116	Fallopian Tube Lesions in Women at High Risk for Ovarian Cancer: A Multicenter Study. <i>Cancer Prevention Research</i> , <b>2018</b> , 11, 697-706	3.2	33
115	Inactivating ARID1A Tumor Suppressor Enhances TERT Transcription and Maintains Telomere Length in Cancer Cells. <i>Journal of Biological Chemistry</i> , <b>2016</b> , 291, 9690-9	5.4	32
114	The Role of E-cadherin in the Motility and Invasion of Implantation Site Intermediate Trophoblast. <i>Placenta</i> , <b>2002</b> , 23, 706-15	3.4	32

113	Apply innovative technologies to explore cancer genome. <i>Current Opinion in Oncology</i> , <b>2005</b> , 17, 33-8	4.2	31
112	Assessing tumors in living animals through measurement of urinary beta-human chorionic gonadotropin. <i>Nature Medicine</i> , <b>2000</b> , 6, 711-4	50.5	31
111	Laminin C1 expression by uterine carcinoma cells is associated with tumor progression. <i>Gynecologic Oncology</i> , <b>2015</b> , 139, 338-44	4.9	30
110	Rsf-1, a chromatin remodelling protein, interacts with cyclin E1 and promotes tumour development. <i>Journal of Pathology</i> , <b>2013</b> , 229, 559-68	9.4	29
109	Molecular genetic analysis of appendiceal mucinous adenomas in identical twins, including one with pseudomyxoma peritonei. <i>American Journal of Surgical Pathology</i> , <b>2001</b> , 25, 1095-9	6.7	29
108	Low-grade serous ovarian cancer: State of the science. <i>Gynecologic Oncology</i> , <b>2020</b> , 156, 715-725	4.9	28
107	Methylomic Analysis of Ovarian Cancers Identifies Tumor-Specific Alterations Readily Detectable in Early Precursor Lesions. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 6536-6547	12.9	28
106	RSF1 is a positive regulator of NF- $\kappa$ B-induced gene expression required for ovarian cancer chemoresistance. <i>Cancer Research</i> , <b>2014</b> , 74, 2258-69	10.1	27
105	Characterization of the immune cell repertoire in the normal fallopian tube. <i>International Journal of Gynecological Pathology</i> , <b>2014</b> , 33, 581-91	3.2	27
104	Expression and clinical role of the bric-a-brac tramtrack broad complex/poxvirus and zinc protein NAC-1 in ovarian carcinoma effusions. <i>Human Pathology</i> , <b>2007</b> , 38, 1030-1036	3.7	27
103	Assessing aneuploidy with repetitive element sequencing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2020</b> , 117, 4858-4863	11.5	26
102	Precursors of ovarian cancer in the fallopian tube: serous tubal intraepithelial carcinoma--an update. <i>Journal of Obstetrics and Gynaecology Research</i> , <b>2015</b> , 41, 6-11	1.9	26
101	Nuclear size distinguishes low- from high-grade ovarian serous carcinoma and predicts outcome. <i>Human Pathology</i> , <b>2005</b> , 36, 1049-54	3.7	26
100	Identification of PBX1 target genes in cancer cells by global mapping of PBX1 binding sites. <i>PLoS ONE</i> , <b>2012</b> , 7, e36054	3.7	26
99	Mutant BRAF induces DNA strand breaks, activates DNA damage response pathway, and up-regulates glucose transporter-1 in nontransformed epithelial cells. <i>American Journal of Pathology</i> , <b>2012</b> , 180, 1179-1188	5.8	25
98	Telomere length in different histologic types of ovarian carcinoma with emphasis on clear cell carcinoma. <i>Modern Pathology</i> , <b>2011</b> , 24, 1139-45	9.8	25
97	Diagnostic potential of tumor DNA from ovarian cyst fluid. <i>ELife</i> , <b>2016</b> , 5,	8.9	25
96	The pathogenesis of atypical proliferative Brenner tumor: an immunohistochemical and molecular genetic analysis. <i>Modern Pathology</i> , <b>2014</b> , 27, 231-7	9.8	24

95	NAC1 is an actin-binding protein that is essential for effective cytokinesis in cancer cells. <i>Cancer Research</i> , <b>2012</b> , 72, 4085-96	10.1	24
94	Application of human leukocyte antigen-G expression in the diagnosis of human cancer. <i>Human Immunology</i> , <b>2007</b> , 68, 272-6	2.3	24
93	Molecular Classification and Emerging Targeted Therapy in Endometrial Cancer. <i>International Journal of Gynecological Pathology</i> , <b>2020</b> , 39, 26-35	3.2	24
92	The Origin of Ovarian Cancer Species and Precancerous Landscape. <i>American Journal of Pathology</i> , <b>2021</b> , 191, 26-39	5.8	24
91	ARID1A immunohistochemistry improves outcome prediction in invasive urothelial carcinoma of urinary bladder. <i>Human Pathology</i> , <b>2014</b> , 45, 2233-9	3.7	23
90	Increased proliferation in atypical hyperplasia/endometrioid intraepithelial neoplasia of the endometrium with concurrent inactivation of ARID1A and PTEN tumour suppressors. <i>Journal of Pathology: Clinical Research</i> , <b>2015</b> , 1, 186-93	5.3	23
89	Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. <i>Cancer</i> , <b>2019</b> , 125, 1963-1972	6.4	22
88	The novel ZIP4 regulation and its role in ovarian cancer. <i>Oncotarget</i> , <b>2017</b> , 8, 90090-90107	3.3	22
87	The role of forkhead box Q1 transcription factor in ovarian epithelial carcinomas. <i>International Journal of Molecular Sciences</i> , <b>2012</b> , 13, 13881-93	6.3	21
86	Measurement of cyclin E genomic copy number and strand length in cell-free DNA distinguish malignant versus benign effusions. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 5805-9	12.9	20
85	Activation of mitogen-activated protein kinase is required for migration and invasion of placental site trophoblastic tumor. <i>American Journal of Pathology</i> , <b>2005</b> , 167, 879-85	5.8	20
84	Adenocarcinoma of Mullerian origin: review of pathogenesis, molecular biology, and emerging treatment paradigms. <i>Gynecologic Oncology Research and Practice</i> , <b>2015</b> , 2, 1	4.5	19
83	Dysfunction of nucleus accumbens-1 activates cellular senescence and inhibits tumor cell proliferation and oncogenesis. <i>Cancer Research</i> , <b>2012</b> , 72, 4262-75	10.1	19
82	Trophoblastic vasculogenic mimicry in gestational choriocarcinoma. <i>Modern Pathology</i> , <b>2011</b> , 24, 646-52	9.8	19
81	Inhibition of the MYC-Regulated Glutaminase Metabolic Axis Is an Effective Synthetic Lethal Approach for Treating Chemoresistant Ovarian Cancers. <i>Cancer Research</i> , <b>2020</b> , 80, 4514-4526	10.1	19
80	Genomic characterization of genes encoding histone acetylation modulator proteins identifies therapeutic targets for cancer treatment. <i>Nature Communications</i> , <b>2019</b> , 10, 733	17.4	19
79	Long Interspersed Nuclear Element 1 Retrotransposons Become Deregulated during the Development of Ovarian Cancer Precursor Lesions. <i>American Journal of Pathology</i> , <b>2019</b> , 189, 513-520	5.8	19
78	Cell cycle-dependent alteration in NAC1 nuclear body dynamics and morphology. <i>Physical Biology</i> , <b>2011</b> , 8, 015005	3	18

77	Loss of ARID1A expression in endometrial samplings is associated with the risk of endometrial carcinoma. <i>Gynecologic Oncology</i> , <b>2018</b> , 150, 426-431	4.9	17
76	Rsf-1 (HBXAP) expression is associated with advanced stage and lymph node metastasis in ovarian clear cell carcinoma. <i>International Journal of Gynecological Pathology</i> , <b>2011</b> , 30, 30-5	3.2	17
75	KDDN: an open-source Cytoscape app for constructing differential dependency networks with significant rewiring. <i>Bioinformatics</i> , <b>2015</b> , 31, 287-9	7.2	16
74	High level of chromosomal aberration in ovarian cancer genome correlates with poor clinical outcome. <i>Gynecologic Oncology</i> , <b>2013</b> , 128, 500-5	4.9	16
73	Metastatic epithelioid trophoblastic tumor in a male patient with mixed germ-cell tumor of the testis. <i>American Journal of Surgical Pathology</i> , <b>2009</b> , 33, 1902-5	6.7	16
72	T cell-inflamed phenotype and increased Foxp3 expression in infiltrating T-cells of mismatch-repair deficient endometrial cancers. <i>Modern Pathology</i> , <b>2019</b> , 32, 576-584	9.8	16
71	Tubal origin of ovarian cancer—the double-edged sword of haemoglobin. <i>Journal of Pathology</i> , <b>2017</b> , 242, 3-6	9.4	15
70	Inhibition of ovarian tumor cell invasiveness by targeting SYK in the tyrosine kinase signaling pathway. <i>Oncogene</i> , <b>2018</b> , 37, 3778-3789	9.2	15
69	Identification of the NAC1-regulated genes in ovarian cancer. <i>American Journal of Pathology</i> , <b>2014</b> , 184, 133-40	5.8	15
68	Evolution of a trophoblastic tumor from an endometrioid carcinoma—a morphological and molecular analysis. <i>International Journal of Gynecological Pathology</i> , <b>2011</b> , 30, 117-20	3.2	15
67	Clinicopathologic and Molecular Features of Paired Cases of Metachronous Ovarian Serous Borderline Tumor and Subsequent Serous Carcinoma. <i>American Journal of Surgical Pathology</i> , <b>2019</b> , 43, 1462-1472	6.7	15
66	Loss of ALDH1A1 expression is an early event in the pathogenesis of ovarian high-grade serous carcinoma. <i>Modern Pathology</i> , <b>2015</b> , 28, 437-45	9.8	14
65	Profiling the activity of G proteins in patient-derived tissues by rapid affinity-capture of signal transduction proteins (GRASP). <i>Proteomics</i> , <b>2004</b> , 4, 812-8	4.8	14
64	Molecular analysis of ovarian mucinous carcinoma reveals different cell of origins. <i>Oncotarget</i> , <b>2015</b> , 6, 22949-58	3.3	14
63	Lack of a y-chromosomal complement in the majority of gestational trophoblastic neoplasms. <i>Journal of Oncology</i> , <b>2010</b> , 2010, 364508	4.5	13
62	Loss of NAC1 expression is associated with defective bony patterning in the murine vertebral axis. <i>PLoS ONE</i> , <b>2013</b> , 8, e69099	3.7	13
61	Inactivation of Arid1a in the endometrium is associated with endometrioid tumorigenesis through transcriptional reprogramming. <i>Nature Communications</i> , <b>2020</b> , 11, 2717	17.4	12
60	Mutation of NRAS is a rare genetic event in ovarian low-grade serous carcinoma. <i>Human Pathology</i> , <b>2017</b> , 68, 87-91	3.7	12

59	DNA Damage Response is Prominent in Ovarian High-Grade Serous Carcinomas, Especially Those with Rsf-1 (HBXAP) Overexpression. <i>Journal of Oncology</i> , <b>2012</b> , 2012, 621685	4.5	12
58	Placental site trophoblastic tumor--past as prologue. <i>Gynecologic Oncology</i> , <b>2001</b> , 82, 413-4	4.9	12
57	Dedifferentiated endometrioid adenocarcinoma: An under-recognized but aggressive tumor?. <i>Gynecologic Oncology Case Reports</i> , <b>2013</b> , 5, 25-7		11
56	Power of the eternal youth: Nanog expression in the gestational choriocarcinoma. <i>American Journal of Pathology</i> , <b>2008</b> , 173, 911-4	5.8	11
55	Proteome-wide Tyrosine Phosphorylation Analysis Reveals Dysregulated Signaling Pathways in Ovarian Tumors. <i>Molecular and Cellular Proteomics</i> , <b>2019</b> , 18, 448-460	7.6	11
54	TET1 reprograms the epithelial ovarian cancer epigenome and reveals casein kinase 2 $\alpha$ as a therapeutic target. <i>Journal of Pathology</i> , <b>2019</b> , 248, 363-376	9.4	10
53	Osteopontin expression in ovarian carcinoma effusions is related to improved clinical outcome. <i>Human Pathology</i> , <b>2011</b> , 42, 991-7	3.7	10
52	Mutation of PPP2R1A: a new clue in unveiling the pathogenesis of uterine serous carcinoma. <i>Journal of Pathology</i> , <b>2011</b> , 224, 1-4	9.4	10
51	Elucidating the pathogenesis of synchronous and metachronous tumors in a woman with endometrioid carcinomas using a whole-exome sequencing approach. <i>Journal of Physical Education and Sports Management</i> , <b>2017</b> , 3,	2.8	10
50	Genome-wide mutation analysis in precancerous lesions of endometrial carcinoma. <i>Journal of Pathology</i> , <b>2021</b> , 253, 119-128	9.4	10
49	Gestational Trophoblastic Tumors and Related Tumor-Like Lesions <b>2011</b> , 1075-1135		10
48	Immunohistochemical expression of ARID1A in penile squamous cell carcinomas: a tissue microarray study of 112 cases. <i>Human Pathology</i> , <b>2015</b> , 46, 761-6	3.7	9
47	Identification and characterization of membralin, a novel tumor-associated gene, in ovarian carcinoma. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , <b>2005</b> , 1730, 96-102		9
46	Epigenomic Reprogramming toward Mesenchymal-Epithelial Transition in Ovarian-Cancer-Associated Mesenchymal Stem Cells Drives Metastasis. <i>Cell Reports</i> , <b>2020</b> , 33, 108473	10.6	8
45	Precancerous Lesions of Ovarian Cancer-A US Perspective. <i>Journal of the National Cancer Institute</i> , <b>2018</b> , 110, 692-693	9.7	8
44	Expression of the chromatin remodeling factor Rsf-1 is down-regulated in breast carcinoma effusions. <i>Human Pathology</i> , <b>2008</b> , 39, 616-22	3.7	8
43	Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer. <i>Gynecologic Oncology</i> , <b>2021</b> , 163, 246-253	4.9	8
42	Epithelial Cells in Endometriosis and Adenomyosis Upregulate STING Expression. <i>Reproductive Sciences</i> , <b>2020</b> , 27, 1276-1284	3	7



41	Oncogenic BRAF and KRAS mutations in endosalpingiosis. <i>Journal of Pathology</i> , <b>2020</b> , 250, 148-158	9.4	7
40	Spleen tyrosine kinase activity regulates epidermal growth factor receptor signaling pathway in ovarian cancer. <i>EBioMedicine</i> , <b>2019</b> , 47, 184-194	8.8	6
39	CINdex: A Bioconductor Package for Analysis of Chromosome Instability in DNA Copy Number Data. <i>Cancer Informatics</i> , <b>2017</b> , 16, 1176935117746637	2.4	6
38	Rationale for Developing a Specimen Bank to Study the Pathogenesis of High-Grade Serous Carcinoma: A Review of the Evidence. <i>Cancer Prevention Research</i> , <b>2016</b> , 9, 713-20	3.2	6
37	CHIP-BIT: Bayesian inference of target genes using a novel joint probabilistic model of CHIP-seq profiles. <i>Nucleic Acids Research</i> , <b>2016</b> , 44, e65	20.1	6
36	Epithelial Tumors of the Ovary <b>2019</b> , 841-966		6
35	Pathology and Pathogenesis of Adenomyosis. <i>Seminars in Reproductive Medicine</i> , <b>2020</b> , 38, 108-118	1.4	6
34	Urothelial Carcinomas With Trophoblastic Differentiation, Including Choriocarcinoma: Clinicopathologic Series of 16 Cases. <i>American Journal of Surgical Pathology</i> , <b>2020</b> , 44, 1322-1330	6.7	6
33	Uterine serous carcinoma: key advances and novel treatment approaches. <i>International Journal of Gynecological Cancer</i> , <b>2021</b> , 31, 1165-1174	3.5	6
32	BACOM2.0 facilitates absolute normalization and quantification of somatic copy number alterations in heterogeneous tumor. <i>Scientific Reports</i> , <b>2015</b> , 5, 13955	4.9	5
31	Analysis of Telomere Lengths in p53 Signatures and Incidental Serous Tubal Intraepithelial Carcinomas Without Concurrent Ovarian Cancer. <i>American Journal of Surgical Pathology</i> , <b>2019</b> , 43, 1083-1091	6.7	5
30	Gestational Trophoblastic Lesions <b>2009</b> , 645-665		4
29	-mutated ovarian serous borderline tumors are at relatively low risk for progression to serous carcinoma. <i>Oncotarget</i> , <b>2019</b> , 10, 6870-6878	3.3	4
28	Expression Patterns of VEGF and Flk-1 in Human Endometrium during the Menstrual Cycle. <i>Journal of Reproduction and Infertility</i> , <b>2015</b> , 16, 3-9	1.5	4
27	Methylomic Landscapes of Ovarian Cancer Precursor Lesions. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 6310-6320	2.9	4
26	Dendritic cells transduced with Rsf-1/HBXAP gene generate specific cytotoxic T lymphocytes against ovarian cancer in vitro. <i>Biochemical and Biophysical Research Communications</i> , <b>2010</b> , 394, 633-8	3.4	3
25	NAC1 attenuates BCL6 negative autoregulation and functions as a BCL6 coactivator of FOXQ1 transcription in cancer cells. <i>Aging</i> , <b>2020</b> , 12, 9275-9291	5.6	3
24	Pathogenesis of Gestational Trophoblastic Lesions <b>2007</b> , 157-166		3

23	Advances in the diagnosis of gestational trophoblastic tumors and tumor-like lesions. <i>Expert Opinion on Medical Diagnostics</i> , <b>2009</b> , 3, 371-80		2
22	Reply to Haffner et al.: DNA hypomethylation renders tumors more immunogenic. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2018</b> , 115, E8583-E8584	11.5	2
21	Biologically inspired survival analysis based on integrating gene expression as mediator with genomic variants. <i>Computers in Biology and Medicine</i> , <b>2016</b> , 77, 231-9	7	1
20	Screening for Ovarian Cancer: A Reality Check. <i>Current Obstetrics and Gynecology Reports</i> , <b>2013</b> , 2, 73-75	0.6	1
19	Pathogenesis and new therapeutic targets of ovarian cancer. <i>Journal of Oncology</i> , <b>2012</b> , 2012, 867512	4.5	1
18	Genomic and network analysis to study the origin of ovarian cancer. <i>Systems Biomedicine (Austin, Tex)</i> , <b>2013</b> , 1, 55-64		1
17	Detecting aberrant signal transduction pathways from high-throughput data using GIST algorithm <b>2012</b> ,		1
16	Biomarker Identification by Knowledge-Driven Multi-Level ICA and Motif Analysis <b>2007</b> ,		1
15	Development of small molecule inhibitors targeting PBX1 transcription signaling as a novel cancer therapeutic strategy. <i>iScience</i> , <b>2021</b> , 24, 103297	6.1	1
14	Sub-millimeter endoscope demonstrates feasibility of in vivo reflectance imaging, fluorescence imaging, and cell collection in the fallopian tubes. <i>Journal of Biomedical Optics</i> , <b>2021</b> , 26,	3.5	1
13	Molecular Pathology of Ovarian Cancer <b>2013</b> , 129-149		1
12	Follicular fluid has more to offer: Insulin-like growth factor axis on ovarian carcinogenesis. <i>EBioMedicine</i> , <b>2019</b> , 41, 30-31	8.8	0
11	Progestin and aromatase inhibitor therapy in recurrent, estrogen/progestin receptor positive uterine carcinosarcoma: A case report.. <i>Gynecologic Oncology Reports</i> , <b>2021</b> , 38, 100877	1.3	0
10	Expression of Cell Competition Markers at the Interface between p53 Signature and Normal Epithelium in the Human Fallopian Tube. <i>PLoS ONE</i> , <b>2016</b> , 11, e0156069	3.7	0
9	A novel human endometrial epithelial cell line for modeling gynecological diseases and for drug screening. <i>Laboratory Investigation</i> , <b>2021</b> , 101, 1505-1512	5.9	0
8	Mutation and methylation profiles of ectopic and eutopic endometrial tissues. <i>Journal of Pathology</i> , <b>2021</b> , 255, 387-398	9.4	0
7	Cytomorphologic and molecular analyses of fallopian tube fimbrial brushings for diagnosis of serous tubal intraepithelial carcinoma. <i>Cancer Cytopathology</i> , <b>2019</b> , 127, 192-201	3.9	
6	Gestational Trophoblastic Tumors and Related Tumorlike Lesions <b>2019</b> , 1307-1375		

- 5 Discriminant and Network Analysis to Study Origin of Cancer **2013**, 193-214
- 4 Epithelial Tumors of the Ovary **2018**, 1-128
- 3 Gestational Trophoblastic Lesions **2020**, 871-903
- 2 Epithelial Tumors of the Ovary **2018**, 1-128
- 1 Gestational Trophoblastic Tumors and Related Tumorlike Lesions **2018**, 1-71